The size of the Latin American non-invasive prenatal testing market was valued at USD 0.32 Billion in 2022. It is further projected to be growing at a CAGR of 11.3% and worth USD 0.55 Billion by 2027.
The term "maternal age" refers to a woman's age at the time of delivery. Increasing maternal age can lead to a variety of health issues, including decreased fertility, high blood pressure, and a higher chance of miscarriage, stillbirths, and maternal mortality. Furthermore, as a result of faulty chromosomal division, maternal age can raise the incidence of genetic abnormalities in newborns. Microcephaly, a short neck, upward slanted eyes, weak muscular tone, and heart, gut, and breathing difficulties are some of the anomalies that can occur in neonates. According to the findings, there has been an increase in maternal advanced age, which is likely to lead to more health difficulties.
In pregnant mothers, early diagnosis of genetic disorders caused by aberrant chromosomal division is becoming increasingly critical. DNA in maternal plasma/foetal cells in maternal blood can also be detected through non-invasive prenatal testing. NIPT testing will become more important in Latin America as maternal age and the incidence of chromosomal problems rise. Increased healthcare infrastructure, rising public healthcare spending, the presence of a large patient population, and the expanding availability of contemporary healthcare technologies are a few of the key factors driving the non-invasive prenatal testing market in the Latin American region.
A variety of factors influence the amount of foetal fraction in the blood. One such factor is maternal weight, which has a considerable impact on the amount of foetal fraction in maternal blood. Because obese women's plasma contains little amounts of foetal DNA, it may not yield accurate results when testing for trisomy and other abnormalities. As a result, patients who weigh more than 250 pounds may have inconclusive results (Source: Non-invasive Prenatal Testing Services to Change for Texas Medicaid, March 2016). This makes NIPT ineffective for detecting chromosomal abnormalities in obese women. Furthermore, positive NIPT results may necessitate a confirmation test using invasive techniques like as amniocentesis and CVS.
This research report on the Latin America non-invasive prenatal testing market has been segmented and sub-segmented into the following categories.
By Instruments:
By Method:
By Application:
By End User:
By Country:
Geographically, the Latin American region is predicted to record a healthy CAGR during the forecast period due to the factors such as the high prevalence of genetic disorders across a large population base, growing awareness about genetic abnormalities, technological advancements, and customer preference for non-invasive techniques over invasive techniques. One of the market's significant limitations is the lack of clinical validity of non-invasive prenatal testing results.
Several laboratories and corporations have struck distribution partnerships with test providers in order to give advanced products and services to patients, which is further expected to encourage the market growth in this region during the forecast period. Key market players can expect considerable development prospects in emerging countries such as Brazil and Mexico in the next years.
The Brazilian market is forecasted to dominate the Latin American Non-Invasive Prenatal Testing Market throughout the forecast period. Obstetricians are increasingly promoting non-invasive testing as an alternative to invasive procedures and for initial diagnostic screening during pregnancy. Argentina leads the Non-Invasive Prenatal Testing Market in Latin America, followed by Brazil. This region's market growth is being driven by quickly expanding healthcare infrastructure, awareness programmes and conferences, and the growing attention of prominent players to expand their footprint.
KEY MARKET PLAYERS:
Companies playing a key role in the Latin America non-invasive prenatal testing market profiled in the report are GE Healthcare (U.S.), Koninklijke Philips N.V. (Netherlands), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.), and Beijing Genomics Institute (China).
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Instruments
5.1.1 Introduction
5.1.2 PCR
5.1.3 Ultrasound
5.1.4 NGS
5.1.5 Microarray
5.1.6 Y-o-Y Growth Analysis, By Instruments
5.1.7 Market Attractiveness Analysis, By Instruments
5.1.8 Market Share Analysis, By Instruments
5.2 Method
5.2.1 Introduction
5.2.2 FCMB
5.2.3 Cell-Free DNA (cf-DNA)
5.2.4 Y-o-Y Growth Analysis, By Method
5.2.5 Market Attractiveness Analysis, By Method
5.2.6 Market Share Analysis, By Method
5.3 Application
5.3.1 Introduction
5.3.2 Trisomy
5.3.3 Microdeletion
5.3.4 Genetics
5.3.5 Rh factor
5.3.6 Y-o-Y Growth Analysis, By Application
5.3.7 Market Attractiveness Analysis, By Application
5.3.8 Market Share Analysis, By Application
5.4 End User
5.4.1 Introduction
5.4.2 Hospital
5.4.3 Diagnostic Labs
5.4.4 Y-o-Y Growth Analysis, By End User
5.4.5 Market Attractiveness Analysis, By End User
5.4.6 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Instruments
6.1.3.3 By Method
6.1.3.4 By Application
6.1.3.5 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Instruments
6.1.4.3 By Method
6.1.4.4 By Application
6.1.4.5 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Instruments
6.1.5.3 By Method
6.1.5.4 By Application
6.1.5.5 By End User
6.2 Brazil
6.3 Mexico
6.4 Rest of Latin America
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 GE Healthcare
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Koninklijke Philips N.V
8.3 Thermo Fisher Scientific
8.4 Hoffman-La Roche
8.5 Pacific Biosciences of California
8.6 PerkinElmer
8.7 QIAGEN N.V
8.8 Agilent Technologies
8.9 Beijing Genomics Institute
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
